Executive Summary
Propanc Biopharma Inc (PPCB) reported a Q3 2024 quarter with no reported revenue and continued heavy losses, underscored by a precarious liquidity position and a materially insolvent balance sheet. The company posted an operating loss of $420,867 and a net loss of $526,700 for the period, with an implied cash burn of $102,810 from operating activities and a minimal cash balance of $6,222 at quarter-end. Interest expense, depreciation, and other non-operating charges contributed to a negative EBITDA of $389,061. While net income improved modestly on a year-over-year basis in the reported metrics (net income up ~34.98% YoY and earnings per share up ~71.14% QoQ), the absolute level of activity remains qualitatively muted and the cash runway is exceptionally short. The quarter’s results reflect PPCB’s status as a preclinical biotech with no product revenue, dependence on external financing, and a balance sheet dominated by liabilities and negative stockholders’ equity, raising compelling questions about liquidity, funding strategy, and long-term viability absent near-term clinical or partnership milestones.
Key Performance Indicators
QoQ: 71.14% | YoY:-70 559.52%
Key Insights
Revenue: None reported (null). Gross Profit: Not disclosed (null). Operating Income: -$420,867, YoY change -9.03%, QoQ change +3.91%. Net Income: -$526,700, YoY +34.98%, QoQ +9.81%. EPS: -$296.77, YoY -70,559.52%, QoQ +71.14%. Cash flow: Net cash from operating activities -$102,810; Free cash flow -$102,810. Cash balance: $6,222 at period end. Balance sheet: Total assets $37,337; Total liabilities $3,736,854; Stockholders’ equity -$3,699,517. Debt: Total debt $932,258; Net debt $926,036. Liqui...
Financial Highlights
Revenue: None reported (null). Gross Profit: Not disclosed (null). Operating Income: -$420,867, YoY change -9.03%, QoQ change +3.91%. Net Income: -$526,700, YoY +34.98%, QoQ +9.81%. EPS: -$296.77, YoY -70,559.52%, QoQ +71.14%. Cash flow: Net cash from operating activities -$102,810; Free cash flow -$102,810. Cash balance: $6,222 at period end. Balance sheet: Total assets $37,337; Total liabilities $3,736,854; Stockholders’ equity -$3,699,517. Debt: Total debt $932,258; Net debt $926,036. Liquidity ratios: Current ratio 0.00349; Quick ratio 0.00349; Cash ratio 0.00169.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Operating Income |
-420.87K |
-9.03% |
3.91% |
| Net Income |
-526.70K |
34.98% |
9.81% |
| EPS |
-296.77 |
-70 559.52% |
71.14% |
Key Financial Ratios
operatingCashFlowPerShare
$-0
priceToBookRatio
-6700.25
priceEarningsRatio
-11766
Management Commentary
No earnings call transcript or management commentary transcript is provided in the data set. As a result, transcript-derived themes or quotes could not be extracted. The analysis below relies on the SEC‑reported financials and the implied narrative from the balance sheet and income statement for Q3 2024.
Forward Guidance
The filing does not include explicit forward guidance or targets from management for QQ4 2024 or beyond. Given the company’s preclinical stage, lack of revenue, and severe liquidity constraints, the near-term guidance would plausibly focus on fundraising plans, potential collaboration/licensing discussions, and any anticipated milestones for the PRP program or other pipeline assets. Investors should monitor management commentary for any indications of planned capital raises, partnerships, or milestone-driven funding, as these would be critical to extending the company’s runway and advancing the pipeline.